Navigation Links
GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011

SAN DIEGO, Nov. 18, 2011 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., today announced study results and the commercial launch of PREvent™. FirstMark PREvent is the first multiple biomarker test that accurately predicts near term (approximately 2-3 years) risk of myocardial infarction (MI) for suspected or confirmed coronary artery disease (CAD) patients. FirstMark PREvent was launched, and the data from the phase I prospective study entitled, "Aggregate Risk Score Based on Markers of Inflammation, Immunity, and Thrombosis is an Independent Predictor of Adverse Cardiovascular Outcomes," was presented by Danny J. Eapen, MD, at the American Heart Association Scientific Sessions 2011 (AHA), in Orlando, Florida.

PREvent is a simple blood test based on technology developed and patented by GenWay, Emory University and MedStar. The test aggregates three biomarkers that identify the multiple pathways that lead to vulnerable plaques. The development and validation studies for the test were comprised of approximately 3,000 individuals with suspected or confirmed CAD. The studies showed PREvent to be significantly more powerful than other tests and risk factors, by identifying the top 10% of confirmed CAD patients that are at a 6.45 times higher risk of a near term MI within a 2-3 year period, as compared to other CAD patients. The test also proved to be 12 times more powerful than the single biomarker CRP. In addition, 18% of CAD patients with all three biomarkers elevated had a major event within the first year, compared to only 2% of CAD patients with normal biomarker levels.

PREvent is a critical advancement in cardiovascular medicine addressing the unmet need to access risk of near term MI. "This simple blood test is an exciting development for suspected or confirmed CAD patients, allowing physician's diagnostic clarity in identifying CAD patients that are in most urgent need of aggressive treatment and monitoring," said Thomas Silberg, President and CEO of GenWay Biotech. FirstMark PREvent is now available and will be targeted to primary care physicians and cardiologists.

The AHA Scientific Sessions 2011 abstract and additional information about the test is available at

About GenWay Biotech, Inc.
GenWay Biotech, is comprised of three divisions. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. GenWay's catalog products and custom services divisions are focused on protein and antibody solutions. GenWay's headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area.

Media Contact: Deborah Moore GenWay Biotech, Inc., 858-458-0855,

News distributed by PR Newswire iReach:

SOURCE GenWay Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Acquires Seppro(R) Depletion Technology From GenWay Biotech
2. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
3. Yongye Biotechnology International Retains CCG Investor Relations
4. ThirdBiotech Announces Kemeta as Newest Sponsor
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
7. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
8. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
9. China Kangtai Cactus Biotech Announces Record Second Quarter Results
10. Yongye Biotechnology International Announces Second Quarter Results
11. Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
Post Your Comments:
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
Breaking Biology Technology:
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):